ArticleAdvances in ophthalmology practice and research
Functional characterization of LSM12 as a driver in uveal melanoma oncogenesis.
Article in Advances in ophthalmology practice and research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the role of LSM12 in uveal melanoma (UM) oncogenesis and progression, examining its potential as both a prognostic biomarker and therapeutic target. Methods: LSM12 expression was analyzed in relation to RNA modification genes and tumor stemness in UM. UM cell lines were subjected to LSM12 knockdown using siRNA, followed by cell viability and migration assays. The therapeutic potential of targeting LSM12 was evaluated using a subcutaneous xenograft model. Additionally, the relationship between LSM12 and the PI3K/Akt/mTOR pathway was explored. Results: LSM12 expression levels were significantly elevated in UM patients, correlating strongly with poor prognosis. Positive correlations were observed between LSM12 expression and multiple genes associated with RNA methylation modifications and cancer stem cell characteristics. Knockdown of LSM12 effectively disrupted UM cell viability and migration in vitro and inhibited OCM1 xenograft growth in vivo. Additionally, LSM12 knockdown resulted in notable inhibition of the PI3K/Akt/mTOR pathway both in vitro and in vivo. Conclusions: Elevated LSM12 expression correlates with poor prognosis in UM and critically promotes oncogenic processes, including tumor cell viability, migration, and tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.